Sun Pharma has received a warning letter from the US FDA for manufacturing practice violations at its Dadra unit. This follows an earlier audit and action notice by the US regulator. The ...
The topical manufacturing facility had completed the USFDA audit during December 16-20, 2019. After the inspection, the plant received zero 483 observations. Hence, the facility located at ...
The company's topical manufacturing facility at Ahmedabad has received an EIR from the United States Food and Drug Administration (USFDA) signifying the successful closure of the audit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback